The product was developed as part of the state strategy for increasing the population's life expectancy and quality of life and improving medicine availability.
The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus.
To expand on the news about GEROPHARM's release of Semavic®, the company has introduced Semavic® as a domestic analogue to Ozempic®, responding to the cessation of Ozempic® imports from Denmark to Russia.
The Ministry of Health of the Russian Federation has authorized a Russian originator drug for the treatment of unresectable or metastatic melanoma. The product was developed by BIOCAD, a biotechnology company; it is a fixed dose combination of two monoclonal antibodies, nurulimab and prolgolimab.
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches.